Experimental vaccines may extend life in pancreatic cancer

January 14, 2014 by Steven Reinberg, Healthday Reporter
Experimental vaccines may extend life in pancreatic cancer
Treatment is less toxic than chemotherapy, researchers find.

(HealthDay)—Patients with advanced pancreatic cancer, one of the most deadly malignancies, may live a little longer when treated with two therapeutic vaccines, new research suggests.

In a study of 90 , this combination approach—GVAX Pancreas followed by CRS-207 vaccine—improved survival by several months compared with GVAX alone, researchers found. The greatest gain was seen in patients who had at least two doses of GVAX and at least one dose of CRS-207, they noted.

"Average survival was basically double among those who received the combination compared with the control group," said Stephen Isaacs, CEO of Aduro BioTech of Berkeley, Calif., which makes the vaccines and funded the trial.

Isaacs believes the effect would be even more dramatic for patients given the vaccines in an early stage of the disease.

"I think these vaccines may offer hope to patients in what has been a fairly dismal prognosis due to the severity of the disease," he said.

Dr. Vincent Vinciguerra, a professor of medicine at Hofstra North Shore-LIJ School of Medicine in New York, said this approach is more targeted than chemotherapy and much less toxic.

"The hope with the vaccine is that you can attack the cancer cells by altering the ," said Vinciguerra, who was not involved in the study.

In the United States each year, more than 45,000 people are diagnosed with pancreatic cancer and upwards of 38,000 die from it. Because it doesn't cause symptoms right away, pancreatic cancer is often caught late, when it is harder to treat.

In a trial just getting underway, the researchers will compare the vaccine duo against CRS-207 alone in 240 patients, Isaacs said. This data is needed before the U.S. Food and Drug Administration will allow use of the two vaccines in a larger group, he said.

Isaacs said the treatment, if approved, will cost $50,000 or more.

The results of this phase 2 study are scheduled for presentation Friday at a meeting of the American Society of Clinical Oncology in San Francisco.

"This study was remarkable in that it demonstrated an improvement in overall survival and appeared to be associated with very few side effects," said Dr. Donald Richards, a pancreatic cancer specialist at Texas Oncology-Tyler, a U.S. Oncology Network affiliate.

"The role of immunotherapy in the treatment of cancer is one of the most exciting fields right now in development," added Richards, who wasn't involved in the research. "This is one of the first studies in pancreatic cancer to show benefit in a very difficult disease to treat."

For the study, researchers randomly assigned 90 patients with advanced pancreatic cancer to GVAX followed by CRS-207 or GVAX alone. Almost all the patients had undergone at least one course of chemotherapy before the trial.

The investigators found that patients who received the two vaccines lived 6.1 months, compared with 3.9 months for those who received only GVAX.

After a year, almost one-quarter of those treated with the vaccine combination were still alive, compared with 12 percent of those treated with the single vaccine, they added.

Moreover, patients who received at least three doses of both vaccines and those who received two doses of GVAX and at least one dose of CRS-207 survived an average of 9.7 months compared with 4.6 months for those who received GVAX alone, the findings showed.

Side effects of the combination vaccines were relatively mild and did not get worse with each dose, the investigators noted. The most common side effects were fever and chills.

The GVAX vaccine is made up of pancreatic that have been genetically modified to emit a protein that stimulates the immune system. To boost its effectiveness, the vaccine is given with a low dose of a common cancer drug, cyclophosphamide.

The second vaccine, CRS-207, is a weakened form of the bacterium Listeria monocytogenes that is genetically modified so it's safe for humans but still able to stimulate the immune system.

This combination of vaccines enhances a person's own immune system and "trains" it to recognize and attack cells, the researchers explained.

Data and conclusions presented at meetings are typically considered preliminary until published in a peer-reviewed medical journal.

Explore further: Recurrent ovarian cancers respond to cancer vaccine after 'reprogramming' with decitabine

More information: For more information on pancreatic cancer, visit the American Cancer Society.

Related Stories

Recurrent ovarian cancers respond to cancer vaccine after 'reprogramming' with decitabine

January 3, 2014
Treatment with the drug decitabine prior to administration of chemotherapy and a cancer vaccine yielded clinical benefit for women with recurrent ovarian cancer, suggesting that this combinatorial chemoimmunotherapy may provide ...

Personalized vaccine for most lethal type of brain tumor shows promise

December 16, 2013
Patients with recurrent glioblastoma multiforme (GBM) treated with an experimental vaccine made from the patient's own resected tumor tissue showed an improved survival compared with historical patients who received the standard ...

FDA approves Celgene drug for pancreatic cancer

September 7, 2013
Federal regulators have approved Celgene Inc.'s drug Abraxane to treat late-stage pancreatic cancer.

Vaccines might become another way to fight cancer

January 19, 2013
(HealthDay)—Most people think of the flu when the word "vaccine" comes up in conversation, but several vaccines also exist to help prevent cancers.

Breaking down cancer's defense mechanisms

December 20, 2013
A possible new method for treating pancreatic cancer which enables the body's immune system to attack and kill cancer cells has been developed by researchers.

New study finds two-drug combo slows advanced pancreatic cancer

April 3, 2012
The combination of the novel drug TH-302 with the standard drug gemcitabine has shown early signs of delaying the worsening of cancer in patients with advanced pancreatic cancer, a Mayo Clinic-led study has found. This was ...

Recommended for you

Outdoor light at night linked with increased breast cancer risk in women

August 17, 2017
Women who live in areas with higher levels of outdoor light at night may be at higher risk for breast cancer than those living in areas with lower levels, according to a large long-term study from Harvard T.H. Chan School ...

Scientists develop blood test that spots tumor-derived DNA in people with early-stage cancers

August 16, 2017
In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center report they have developed a test that spots tiny amounts of cancer-specific DNA in blood and have used it to ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...

Popular immunotherapy target turns out to have a surprising buddy

August 16, 2017
The majority of current cancer immunotherapies focus on PD-L1. This well studied protein turns out to be controlled by a partner, CMTM6, a previously unexplored molecule that is now suddenly also a potential therapeutic target. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.